Presentation is loading. Please wait.

Presentation is loading. Please wait.

HIV Prevention Research & Development Investment in 2013 In a changing global development, economic, and human rights landscape Presented at the International.

Published byHarry Hackman Modified over 9 years ago

Similar presentations

Presentation on theme: "HIV Prevention Research & Development Investment in 2013 In a changing global development, economic, and human rights landscape Presented at the International."— Presentation transcript:

1 HIV Prevention Research & Development Investment in 2013 In a changing global development, economic, and human rights landscape Presented at the International AIDS & Economics Network Pre-conference, Melbourne, July 2014 Emily Donaldson, AVAC Presenting on behalf of the HIV Vaccines & Microbicides Resource Tracking Working Group

2 Methodology Comprehensive and consistent investment data collection and disaggregation methodology since 2004 Data collection January – June 2014 HIV Vaccines & Microbicides Resource Tracking Working Group Data Sources: Public funders (447 grants) Philanthropic (141 grants) Industry (7 grants) R&D Categories: Preventive HIV vaccines (307 grants) Microbicides (84 grants) Pre-exposure prophylaxis (54 grants) Treatment as prevention (80 grants) Male circumcision (20 grants) Female condom (4 grants) Prevention of vertical transmission (24 grants) HSV-2 vaccines (22 grants) HIV cure (150 grants) Therapeutic HIV vaccines (45 grants)

3 Global HIV Prevention R&D Investment, 2009 – 2013 (US$ millions) US$1.26B US$1.31B US$1.28B US$1.27B US$1.22B HIV Vaccines & Microbicides Resource Tracking Working Group

4 Global HIV Prevention R&D Investment 2013 by Funder Type (US$ millions) HIV Vaccines & Microbicides Resource Tracking Working Group

5 Global HIV Prevention R&D Investment 2012 & 2013 (US$ millions) Funding SourceAmount 2013Amount 2012% Change from 2012 US Public-Sector887925-4% European Public- Sector 7786-10% Other Governments 6569-6% Philanthropic193203-5% Industry3734+9% All HIV Prevention R&D 1.261.31-4% HIV Vaccines & Microbicides Resource Tracking Working Group

6 2013 Investment and Year-Over-Year Change HIV Vaccines & Microbicides Resource Tracking Working Group

7 $154M 2013 International Development Funding HIV Vaccines & Microbicides Resource Tracking Working Group

8 Global HIV Prevention R&D Investment 2013 by Prevention Option (US$ millions) HIV Vaccines & Microbicides Resource Tracking Working Group

9 Global HIV Prevention R&D Investment 2012 & 2013 (US$ millions) HIV Prevention Option Amount 2013Amount 2012% Change from 2012 Preventive HIV vaccines 818847-3% Microbicides210245-14% Pre-exposure Prophylaxis 3631+16% Treatment as Prevention 11798+19% Male circumcision3241.6-23% Female condoms2.22+10% Prevention of vertical transmission 4443.8+0.5% All HIV Prevention R&D 1.261.31-4% HIV Vaccines & Microbicides Resource Tracking Working Group

10 HIV Prevention Trial Participants by Region 2013

11 Advocacy, policy and funding trends The US public sector funds the majority of HIV prevention R&D. Philanthropic organizations increasingly fund vital parts of HIV prevention research. Industry funding stayed almost flat and shifted to later development stages. International development priorities are evolving. The enabling environment has a profound effect on where trials take place and whether they are able to happen. HIV Vaccines & Microbicides Resource Tracking Working Group

12 Acknowledgements Significant contributions from the Working Group organizations, AVAC, the International AIDS Vaccine Initiative (IAVI), and the Joint United Nations Programme on HIV/AIDS (UNAIDS) and Working Group members Kevin Fisher (AVAC), Reuben Granich (UNAIDS), Thomas Harmon (IAVI), Polly Harrison (AVAC) and Mitchell Warren (AVAC).

13 For the full report, including graphics and past reports, visit www.hivresourcetracking.org

Download ppt "HIV Prevention Research & Development Investment in 2013 In a changing global development, economic, and human rights landscape Presented at the International."

Similar presentations

INTERNATIONAL AIDS AND ECONOMICS NETWORK AND THE LATEST RESEARCH IN THE ECONOMICS OF AIDS Steven Forsythe, PhD Health Economist President of the International.

INTERNATIONAL AIDS AND ECONOMICS NETWORK AND THE LATEST RESEARCH IN THE ECONOMICS OF AIDS Steven Forsythe, PhD Health Economist President of the International.
Role of the HIV/AIDS community in science & regulatory advocacy Nikos Dedes European AIDS Treatment Group 22 July 2014, Melbourne.

Role of the HIV/AIDS community in science & regulatory advocacy Nikos Dedes European AIDS Treatment Group 22 July 2014, Melbourne.
Telling Time; Telling the Truth Engaging communities as stakeholders (and partners) in HIV vaccine R&D Mitchell Warren AVAC 2 July 2013 IAS Symposia Session:

Telling Time; Telling the Truth Engaging communities as stakeholders (and partners) in HIV vaccine R&D Mitchell Warren AVAC 2 July 2013 IAS Symposia Session:
From “What If” to “What Now” Perspectives on ARVs and the Future of Treatment and Prevention Mitchell Warren Executive Director, AVAC IAS 2011, Rome.

From “What If” to “What Now” Perspectives on ARVs and the Future of Treatment and Prevention Mitchell Warren Executive Director, AVAC IAS 2011, Rome.
The Development of the “Brazilian Menu of Partnership Options” Betina Durovni*, Maria Etelvina Barros #, Naiara G. da Costa # *Health Secretary Rio de.

The Development of the “Brazilian Menu of Partnership Options” Betina Durovni*, Maria Etelvina Barros #, Naiara G. da Costa # *Health Secretary Rio de.
HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.

HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.
Emily Bass AIDS Vaccine Advocacy Coalition (AVAC) 2 July 2007 HIV Prevention Research and Implementation: Challenges and Opportunities on the Horizon.

Emily Bass AIDS Vaccine Advocacy Coalition (AVAC) 2 July 2007 HIV Prevention Research and Implementation: Challenges and Opportunities on the Horizon.
Public Sector Donors Who Increased Funding for HIV Vaccine R&D in 2011 How much did donor funding increase?

Public Sector Donors Who Increased Funding for HIV Vaccine R&D in 2011 How much did donor funding increase?
The CDC Prevention Grant Funding Opportunity Announcement (FOA) and OA’s Response Overview and Discussion September 21, 2011 California Department of Public.

The CDC Prevention Grant Funding Opportunity Announcement (FOA) and OA’s Response Overview and Discussion September 21, 2011 California Department of Public.
How well are we doing in preventing HIV and how can we do better?

How well are we doing in preventing HIV and how can we do better?
Melbourne, 23 July 2014 - IAS 2014 Fatiha Terki, WFP Critical enablers and synergies including nutrition.

Melbourne, 23 July IAS 2014 Fatiha Terki, WFP Critical enablers and synergies including nutrition.
Modeling Studies in AIDS Vaccine R&D 1 Arne Naeveke Executive Director Advocacy, Policy and Communications IAEN – AIDS 2014 Pre-conference – July 19, 2014,

Modeling Studies in AIDS Vaccine R&D 1 Arne Naeveke Executive Director Advocacy, Policy and Communications IAEN – AIDS 2014 Pre-conference – July 19, 2014,
Methods for Estimating Global Resource Needs for HIV/AIDS 2008-2015 John Stover, Lori Bollinger International AIDS Economic Network Meeting, Washington,

Methods for Estimating Global Resource Needs for HIV/AIDS John Stover, Lori Bollinger International AIDS Economic Network Meeting, Washington,
WHAT IS GOING ON IN HIV AND AIDS IN 2013 AND BEYOND Prof Alan Whiteside RATN MEETING JOHANNESBURG March 2013.

WHAT IS GOING ON IN HIV AND AIDS IN 2013 AND BEYOND Prof Alan Whiteside RATN MEETING JOHANNESBURG March 2013.
The Global Fund's new funding model for more strategic investment Symposia Session - Trends in AIDS Financing and Effectiveness of Current Investments.

The Global Fund's new funding model for more strategic investment Symposia Session - Trends in AIDS Financing and Effectiveness of Current Investments.
AIDS 2014 – Ending the adolescent AIDS epidemic Ungdom og hiv 29.10.2014 Anne May Andersen, Norad.

AIDS 2014 – Ending the adolescent AIDS epidemic Ungdom og hiv Anne May Andersen, Norad.
Innovation to Protect Women’s Reproductive Health in Kenya MULTIPURPOSE PREVENTION TECHNOLOGIES (MPTS) Meeting name Presenter Organization Date.

Innovation to Protect Women’s Reproductive Health in Kenya MULTIPURPOSE PREVENTION TECHNOLOGIES (MPTS) Meeting name Presenter Organization Date.
Rectal Microbicides: The Basics Date, Location Your Name, Organization.

Rectal Microbicides: The Basics Date, Location Your Name, Organization.
HIV/AIDS Treatment and Care Clinical protocols for the WHO European Region 23 November 2007 World AIDS Day Jeffrey V. Lazarus WHO Europe, STI/HIV/AIDS.

HIV/AIDS Treatment and Care Clinical protocols for the WHO European Region 23 November 2007 World AIDS Day Jeffrey V. Lazarus WHO Europe, STI/HIV/AIDS.
Creating an AIDS-Free Generation The beginning of the end of AIDS Center for Strategic & International Studies Washington, DC March 22, 2012 Thomas R.

Creating an AIDS-Free Generation The beginning of the end of AIDS Center for Strategic & International Studies Washington, DC March 22, 2012 Thomas R.

Similar presentations

Ads by Google